Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616795 · ClinicalTrials.gov registry record · Phase 1
Study of LY3154207 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03616795 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 8 participants.
The verdict
NCT03616795, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3154207. This means that a radioactive substance C14 will be incorporated into the study drug, to investigate the study drug and its breakdown products, to find out how much of these pass from blood into urine, feces and expired air. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.
Interventions
- DRUG LY3154207
- DRUG [14C]-LY3154207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2018-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616795
The ClinicalTrials.gov registry entry for NCT03616795 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY3154207 is the first listed.
NCT03616795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03616795 about?
NCT03616795 is a clinical study titled "Study of LY3154207 in Healthy Participants". The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3154207. This means that a radioactive substance C14 will be incorporated into the study dru...
What is the current status of trial NCT03616795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-08-09. Estimated completion is 2018-11-05.
What interventions are being tested in trial NCT03616795?
The interventions under investigation include: LY3154207 (DRUG), [14C]-LY3154207 (DRUG).
Who is sponsoring clinical trial NCT03616795?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.